ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Jul 17, 2026, 10:12Julien Perrin: Presenting Thalassemia Coagulation Research at ISTH 2026
-
Jul 17, 2026, 10:08Cihan Ay: Thank you for making ISTH 2026 such a remarkable congress
-
Jul 17, 2026, 10:06Laura Cunliffe: That Is a Wrap for Meg and Me at ISTH 2026 in Paris
-
Jul 17, 2026, 10:03Roberta Gualtierotti: Updating on the Standardization of ultrasound definitions in hemophilic arthropathy at the ISTH 2026
-
Jul 17, 2026, 09:57Hrushikesh Vyas – A Wonderful Week Presenting Inherited Thrombocytopenia Research at ISTH 2026
-
Jul 17, 2026, 09:42Samin Mohsenian: Proud to Receive a Top Poster Award at ISTH 2026
-
Jul 17, 2026, 09:36Wolfgang Miesbach: A Landmark Case of Supratherapeutic FIX Following Gene Therapy Presented at ISTH 2026
-
Jul 17, 2026, 09:28Lisa Astorga: Leaving ISTH 2026 Inspired by the Global Thrombosis and Hemostasis Community
-
Jul 17, 2026, 09:23Maxime Dely: Honored to Reach My 6th Plasma Donation of 2026